- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02284256
A Safety and Efficacy Study Comparing Fibrocaps and Tachosil in Hepatic Surgery
A Phase 3b, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety Study of Topical FibrocapsTM (RaplixaTM) and Tachosil® in Surgical Hemostasis During Hepatic Resection
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Innsbruck, Austria, A-6020
- Universitaetsklinik Innsbruck
-
Linz, Austria, A-4010
- Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H.
-
Wien, Austria, A-1090
- Medizinische Universitaet Wien AKH
-
-
-
-
-
Aachen, Germany, 52074
- Universitaetsklinikum Aachen, RWTH
-
Berlin, Germany, 13353
- Charité Campus Virchow-Klinikum
-
Frankfurt am Main, Germany, D-60488
- Krankenhaus Nordwest Gmbh
-
Frankfurt am Main, Germany, D-60590
- J. W. Goethe Universitaetsklinik Frankfurt
-
Hamburg, Germany, 20246
- Universitaetsklinikum Hamburg-Eppendorf
-
Hanover, Germany, 30625
- Medizinische Hochschule Hannover
-
Heidelberg, Germany, 69120
- Universitätsklinikum Heidelberg
-
Leipzig, Germany, 04103
- Universitaetsklinikum Leipzig AoeR
-
Muenchen, Germany, 81377
- Klinikum der LMU Muenchen - Campus Grosshadern
-
Munich, Germany
- Klinikum Rechts der Isar Munich
-
Stuttgart, Germany
- Klinikum Stuttgart - Katharinenhospital (KH)
-
Tuebingen, Germany, 72976
- Universitaetsklinikum Tuebingen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (pre-surgery):
- Subject has signed an independent ethics committee (IEC)-approved informed consent document
- Subject is undergoing hepatic wedge resection or anatomic resection of 1 to 5 contiguous hepatic segments, and/or other hepatic surgery, any of which may be combined with other surgical procedures involving the gall bladder or intestines
- Subject age is >18 years at time of consent
- If female and of child-bearing potential, subject has negative pregnancy test during screening and is not breast-feeding
If subject is a sexually active male or a sexually active female of child-bearing potential, subject agrees to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits
Inclusion Criteria (during surgery):
- Presence of mild to moderate bleeding/oozing when control by conventional surgical techniques, including but not limited to suture, ligature and cautery is ineffective or impractical
- Absence of intra-operative complications other than bleeding which, in the opinion of the investigator, may interfere with the assessment of efficacy or safety
- Approximate TBS surface area of ≤ 100 cm^2
Exclusion Criteria:
- Subject has known hypersensitivity to Fibrocaps or any of its components
- Subject has known allergy to porcine gelatin
- Subject has known hypersensitivity to Tachosil or any of the excipients included in Tachosil
- Subject is unwilling to receive blood products
- Subject is having hepatic surgery due to emergency-traumatic event
- Subject requires extrahepatic bile duct resection (common bile duct resection or resection of the bile duct which leads to performing an anastomoses between the bile duct and small bowel) and biliary anastomosis, and/or pancreatic resections
- Subject has any clinically-significant coagulation disorder that may interfere with the assessment of efficacy or pose a safety risk to the subject according to the investigator, or baseline abnormalities of international normalized ratio (INR) > 2.5 or activated partial thromboplastin time (aPTT) > 100 seconds during screening that are not explained by current drug treatment (e.g., warfarin, heparin)
- Subject has a platelet count < 100 x10^9 PLT/L during screening
- Subject has medical, social or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures
- Subject is currently participating or has participated in another clinical study involving another investigational agent within 4 weeks of the planned date of surgery or is planning participation in another clinical trial within 6 weeks after surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Fibrocaps
Human fibrinogen and thrombin powder. Single application during surgery Other Names:
Device: Gelatin sponge. Single application during surgery Other Name: Spongostan |
Other Names:
|
ACTIVE_COMPARATOR: TachoSil
Human fibrinogen and thrombin powder.
Single application during surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to Hemostasis (TTH)
Time Frame: Within 5 minutes of treatment
|
Within 5 minutes of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wolf Bechstein, MD, J.W.Goethe-Universität
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- FC-005
- 2014-000816-32 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surgical Bleeding
-
Dilon Technologies Inc.Syneos HealthCompleted
-
MallinckrodtTerminated
-
MallinckrodtCompletedMild or Moderate Surgical BleedingUnited States, Netherlands, United Kingdom, Belgium
-
Instituto Grifols, S.A.CompletedVascular Surgical BleedingUnited States, Hungary, Russian Federation, Serbia
-
Ethicon, LLCCompleted
-
CryoLife, Inc.United States Department of DefenseTerminatedIntraoperative BleedingUnited States
-
Assiut UniversityUnknownIntraoperative BleedingEgypt
-
Baxter Healthcare CorporationBaxter Innovations GmbHCompletedIntra-operative BleedingCzech Republic, Germany, Hungary, Poland
-
Grifols Biologicals, LLCInstituto Grifols, S.A.CompletedSoft Tissue Surgical BleedingUnited States, Hungary, Serbia
-
Instituto Grifols, S.A.CompletedSafety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open SurgeriesParenchymous Tissue Surgical BleedingUnited States, Hungary, Russian Federation, Serbia
Clinical Trials on Fibrocaps
-
MallinckrodtCompleted
-
MallinckrodtCompletedMild or Moderate Surgical BleedingUnited States, Netherlands, United Kingdom, Belgium
-
MallinckrodtCompleted
-
MallinckrodtTerminated